Clinical Trials Logo

Renal Cancer Cell clinical trials

View clinical trials related to Renal Cancer Cell.

Filter by:
  • None
  • Page 1

NCT ID: NCT03456401 Terminated - Renal Cancer Cell Clinical Trials

Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)

TOKIO
Start date: November 2014
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy with TKIs, in terms of median progression free survival (mPFS), in patients affected by metastatic renal cancer cell. Patients receiving the sequence Sunitinib- Axitinib, will receive Sorafenib. Patients receiving the sequence Pazopanib-Sorafenib, will receive Sunitinib. Sorafenib dosage 400mg orally, twice a day. Sunitinib dosage 50 mg 4 weeks on followed by 2 weeks a rest. The therapy will be continued until disease progression or unacceptable toxicity.